-- 2020 award open for entries for a chance to win €50,000
--
-- Investigator Award recognises individuals making a
difference and reinforces company's ongoing commitment to the
science of immunomodulation through ECP and its therapeutic
applications --
STAINES-UPON-THAMES, United
Kingdom, Oct. 22 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global
biopharmaceutical company, has announced that its 2020 Advancing
Extracorporeal Photopheresis (ECP) Immunomodulation Investigator
Award is open for entries.
As in previous years, the award is intended to recognise and
support the institutions of those individuals who are making a
difference in advancing the knowledge around ECP Immunomodulation
in the EMEA region. With the winning entry receiving an educational
grant of €50,000, this year's award programme supports research
that investigates the overarching immunomodulatory role of ECP
through inflammation control and resolution while specifically
preserving immune function.
The award, now in its third year, was developed by Mallinckrodt to mark 30 years of its pioneering
THERAKOS ECP Immunomodulation™. The Investigator Award reflects the
company's ongoing commitment to the science of immunomodulation
through ECP and its therapeutic applications. The call for entries
is now open and will take submissions until the closing date of
31 January 2020.
"As a pioneer in ECP immunomodulation, Mallinckrodt established the ECP Immunomodulation
Investigator Award to recognise the efforts of those working
in this exciting field of medicine. I urge those involved in ECP
Immunomodulation to submit an entry and so help further the
understanding of immunomodulatory therapy through ECP",
said Steven Romano, M.D.,
Executive Vice President and Chief Scientific Officer of
Mallinckrodt.
Last year's winning entry was submitted by Dr. Rachel Crossland of Newcastle University in the United Kingdom. Her team is investigating the
impact of ECP Immunomodulation on extracellular vesicles and their
profiles in response to therapy in patients with graft-versus-host
disease (GvHD). A major complication affecting between 40-70% of
Hematopoietic Stem Cell Transplant (HSCT) patients, severe GvHD
carries a high mortality rate.1
Full details on how to enter the 2020 ECP Immunomodulation
Investigator Award can be found at
https://www.therakosinstitute.eu/the-mallinckrodt-2020/
ABOUT THERAKOS
Mallinckrodt is the world's only provider of
fully-integrated and validated systems for administering
immunomodulatory therapy through ECP. Its Therakos therapeutic
platforms, including the latest generation THERAKOS™ CELLEX™
Photopheresis System, are used by academic medical centres,
hospitals, and treatment centres in nearly 40 countries and have
delivered more than 1 million treatments globally. For more
information, please visit www.therakos.co.uk.
For important safety information related to the THERAKOS™
CELLEX™ Photopheresis System, please visit
https://www.therakos.co.uk/important-safety-information-hp.
1. Jagasia M, Arora M, Flowers ME, et al. Risk factors for
acute GVHD and survival after hematopoietic cell transplantation,
Blood. 2012 Jan 5;119(1):296-307.
doi: 10.1182/blood-2011-06-364265. Epub 2011 Oct 18.
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of
multiple wholly owned subsidiaries that develop, manufacture,
market and distribute specialty pharmaceutical products and
therapies. The company's Specialty Brands reportable segment's
areas of focus include autoimmune and rare diseases in specialty
areas like neurology, rheumatology, nephrology, pulmonology and
ophthalmology; immunotherapy and neonatal respiratory critical care
therapies; analgesics and gastrointestinal products. Its Specialty
Generics reportable segment includes specialty generic drugs and
active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
EMEA Media Inquiries
James Tate
The Henley Group
+1 44 1491 570 971
james@henley.co.uk
US Media Inquiries
Daniel Yunger
Kekst CNC
+1 212 521 4879
mallinckrodt@kekstcnc.com
Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. © 2019
Mallinckrodt. 9/19 EU-1900122
Logo -
https://mma.prnewswire.com/media/167103/mallinckrodt_plc_logo.jpg